



Herbal Medicine in Diabetes Management: A Review

Pratibha Sen, Somesh Saxena, Dr. Rita Mourya, Dr. Shailesh Jain

SAM College of Pharmacy, SAM Global University, Raisen

ARTICLE INFO

Article History

Received: April 2025

Accepted: May 2025

Keywords: herbal medicine, diabetes mellitus, hypoglycemic plants, complementary medicine, phytotherapy, glucose control, insulin sensitivity, traditional medicine

Corresponding Author

***Pratibha Sen**

ABSTRACT

Diabetes mellitus represents a significant global health challenge, affecting over 537 million adults worldwide. While conventional pharmaceutical interventions remain the cornerstone of diabetes management, there has been growing interest in complementary and alternative medicine approaches, particularly herbal remedies. This review examines the current evidence for herbal medicines in diabetes management, focusing on their mechanisms of action, clinical efficacy, and safety profiles. A systematic analysis of traditional medicinal plants reveals that numerous herbs demonstrate hypoglycemic properties through various mechanisms including enhanced insulin secretion, improved insulin sensitivity, inhibition of carbohydrate-digesting enzymes, and glucose uptake enhancement. Notable herbs such as *Gymnema sylvestre*, *Momordica charantia*, *Trigonella foenum-graecum*, and *Cinnamomum verum* have shown promising results in both preclinical and clinical studies. However, standardization issues, limited high-quality clinical trials, and potential herb-drug interactions remain significant challenges. This review synthesizes current knowledge and identifies areas requiring further research to establish herbal medicines as evidence-based adjuncts to conventional diabetes therapy.

REVIEW ARTICLE

1. INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The International Diabetes Federation estimates that 537 million adults (20-79 years) were living with diabetes in 2021, with projections suggesting this number will rise to 783 million by 2045. The economic burden of diabetes is substantial, with global healthcare expenditure exceeding \$966 billion annually. Traditional medicine systems have utilized plant-based remedies for diabetes-like

symptoms for centuries. The World Health Organization recognizes that approximately 80% of the world's population relies on traditional medicine for primary healthcare needs. In recent decades, scientific interest in herbal antidiabetic agents has intensified, driven by the limitations of conventional therapies, including side effects, cost, and accessibility issues in developing countries. The therapeutic potential of medicinal plants in diabetes management stems from their complex phytochemical compositions, which may offer multiple mechanisms of action and potentially fewer adverse effects compared to

synthetic drugs. This review aims to provide a comprehensive analysis of herbal medicines used in diabetes management, examining their pharmacological mechanisms, clinical evidence, and future therapeutic potential.

2. PATHOPHYSIOLOGY OF DIABETES AND HERBAL INTERVENTION POINTS

Diabetes mellitus encompasses two primary types: Type 1 diabetes (T1DM), characterized by autoimmune destruction of pancreatic β -cells, and Type 2 diabetes (T2DM), involving insulin resistance and progressive β -cell dysfunction. The pathophysiology involves multiple interconnected pathways including glucose metabolism disruption, oxidative stress, inflammation, and complications affecting cardiovascular, renal, and nervous systems.

Herbal medicines can potentially intervene at various points in diabetic pathophysiology. These intervention mechanisms include stimulation of insulin secretion from pancreatic β -cells, enhancement of peripheral glucose utilization, inhibition of hepatic glucose production, modulation of carbohydrate-digesting enzymes, antioxidant activity to reduce oxidative stress, and anti-inflammatory effects to address chronic low-grade inflammation associated with diabetes.

3. MAJOR HERBAL MEDICINES IN DIABETES MANAGEMENT

3.1 *Gymnema sylvestre* (Gurmar)

Gymnema sylvestre, known as "sugar destroyer" in Hindi, has been extensively studied for its antidiabetic properties. The primary bioactive compounds are gymnemic acids, which share structural similarity with glucose molecules. These compounds can block sweet taste receptors and may interfere with glucose absorption in the intestines. Clinical studies have demonstrated significant reductions in fasting blood glucose, postprandial glucose, and HbA1c levels in both T1DM and T2DM patients.

3.2 *Momordica charantia* (Bitter Melon)

Bitter melon contains several compounds with hypoglycemic activity, including charantin, vicine, and polypeptide-p (plant

insulin). These compounds work through multiple mechanisms including enhanced glucose uptake by skeletal muscle, improved insulin secretion, and inhibition of glucose absorption from the intestines. Clinical trials have shown modest but consistent improvements in glycemic control.

3.3 *Trigonella foenum-graecum* (Fenugreek)

Fenugreek seeds are rich in soluble fiber, particularly galactomannan, which slows carbohydrate absorption and improves glucose tolerance. The seeds also contain 4-hydroxyisoleucine, an amino acid that stimulates insulin secretion in a glucose-dependent manner. Multiple clinical studies have demonstrated significant reductions in fasting glucose, postprandial glucose, and HbA1c levels.

3.4 *Cinnamomum verum* (Cinnamon)

Cinnamon contains bioactive compounds including cinnamaldehyde, cinnamic acid, and procyanidin polymers. These compounds enhance insulin sensitivity by activating insulin signaling pathways and improving glucose uptake by muscle cells. Meta-analyses of clinical trials show modest improvements in fasting glucose and insulin sensitivity.

3.5 *Allium sativum* (Garlic)

Garlic contains sulfur compounds, particularly allicin and S-allyl cysteine, which demonstrate hypoglycemic effects through enhanced insulin secretion and improved insulin sensitivity. Additionally, garlic exhibits cardiovascular protective effects, which is particularly relevant for diabetic patients at increased cardiovascular risk.

4. CLINICAL EVIDENCE AND EFFICACY

The clinical evidence for herbal medicines in diabetes management varies considerably across different plants and preparations. While numerous small-scale studies have reported positive outcomes, the overall quality of evidence remains moderate due to methodological limitations, including small sample sizes, short study durations, lack of

standardization, and inconsistent outcome measures.

Systematic reviews and meta-analyses have provided more robust evidence for certain herbs. For instance, meta-analyses of cinnamon supplementation have shown statistically significant but clinically modest improvements in fasting glucose levels. Similarly, systematic reviews of bitter melon studies have demonstrated consistent, though moderate, hypoglycemic effects.

The heterogeneity in study designs, participant populations, and herbal preparations makes direct comparisons challenging. Many studies have been conducted in specific populations, limiting generalizability to broader patient groups. Additionally, the majority of high-quality studies have focused on T2DM, with limited evidence for T1DM applications.

5. MECHANISMS OF ACTION

Herbal antidiabetic compounds work through diverse molecular mechanisms, often targeting multiple pathways simultaneously. The primary mechanisms include direct stimulation of pancreatic β -cells to enhance insulin secretion, improvement of insulin sensitivity in peripheral tissues through activation of insulin signaling pathways, inhibition of key enzymes involved in carbohydrate digestion such as α -amylase and α -glucosidase, enhancement of glucose uptake by skeletal muscle and adipose tissue, inhibition of hepatic glucose production, and modulation of incretin hormones like GLP-1. Secondary mechanisms that contribute to overall metabolic improvement include antioxidant activity to reduce oxidative stress, anti-inflammatory effects to address chronic inflammation, lipid-lowering properties to improve dyslipidemia, and cardiovascular protective effects to reduce diabetes-related complications.

7. Tables

Table 1: Major Antidiabetic Herbs and Their Mechanisms of Action

Herb	Scientific Name	Primary Bioactive Compounds	Main Mechanisms of Action	Clinical Evidence Level

The polypharmacological nature of herbal medicines, where multiple compounds act on different targets simultaneously, may explain their therapeutic potential and relatively favorable safety profiles compared to single-target synthetic drugs.

6. SAFETY AND TOXICOLOGY

While herbal medicines are often perceived as safe due to their natural origin, safety considerations are paramount, particularly for long-term use in chronic conditions like diabetes. The safety profile varies significantly among different herbs, with some demonstrating excellent tolerability while others may cause adverse effects or interact with conventional medications.

Common adverse effects reported with herbal antidiabetic medicines include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. These effects are often dose-dependent and may resolve with continued use or dose adjustment. More serious concerns include hepatotoxicity, which has been reported with certain herbal preparations, and hypoglycemia, particularly when used in combination with conventional antidiabetic medications.

Herb-drug interactions represent a significant safety concern. Many herbal medicines can potentiate the effects of conventional antidiabetic drugs, potentially leading to severe hypoglycemia. Additionally, some herbs may affect the metabolism of other medications through modulation of cytochrome P450 enzymes, altering drug concentrations and efficacy.

Quality control issues, including contamination with heavy metals, pesticides, or adulterants, pose additional safety risks. The lack of standardization in herbal preparations makes it difficult to predict therapeutic outcomes and assess safety profiles accurately.

Gymnema	<i>Gymnema sylvestre</i>	Gymnemic acids	β -cell stimulation, glucose absorption inhibition	Moderate
Bitter Melon	<i>Momordica charantia</i>	Charantin, vicine, polypeptide-p	Insulin-like activity, enhanced glucose uptake	Moderate
Fenugreek	<i>Trigonella foenum-graecum</i>	4-hydroxyisoleucine, galactomannan	Insulin secretion, delayed gastric emptying	Good
Cinnamon	<i>Cinnamomum verum</i>	Cinnamaldehyde, procyanidins	Insulin sensitivity enhancement	Good
Garlic	<i>Allium sativum</i>	Allicin, S-allyl cysteine	Insulin secretion, antioxidant activity	Limited
Ginseng	<i>Panax ginseng</i>	Ginsenosides	Insulin sensitivity, glucose uptake	Moderate
Aloe Vera	<i>Aloe barbadensis</i>	Glucomannan, lectins	Glucose absorption reduction	Limited
Banaba	<i>Lagerstroemia speciosa</i>	Corosolic acid	Glucose transport enhancement	Limited
Ginger	<i>Zingiber officinale</i>	Gingerols, shogaols	Insulin sensitivity, anti-inflammatory	Limited
Turmeric	<i>Curcuma longa</i>	Curcumin	Anti-inflammatory, insulin sensitivity	Moderate

Table 2: Clinical Trial Outcomes of Selected Herbal Medicines

Herb	Study Type	Duration	Sample Size	Primary Outcome	Effect Size	Safety Profile
<i>Gymnema sylvestre</i>	RCT	18-24 months	22-65	HbA1c reduction: 1.7-2.1%	Large	Well tolerated
<i>Momordica charantia</i>	RCT	4-12 weeks	24-100	FBG reduction: 15-25 mg/dL	Moderate	Mild GI effects
<i>Trigonella foenum-graecum</i>	RCT	2-24 weeks	18-154	FBG reduction: 18-35 mg/dL	Moderate-Large	Mild GI effects
<i>Cinnamomum verum</i>	Meta-analysis	4-18 weeks	10-543	FBG reduction: 10-29 mg/dL	Small-Moderate	Generally safe
<i>Allium sativum</i>	RCT	4-24 weeks	25-210	FBG reduction: 8-15 mg/dL	Small	Well tolerated
<i>Panax ginseng</i>	RCT	8-12 weeks	19-36	PPG reduction: 15-20%	Moderate	Mild insomnia
<i>Aloe barbadensis</i>	RCT	6-8 weeks	30-90	FBG reduction: 46-64 mg/dL	Large	Laxative effects

<i>Lagerstroemia speciosa</i>	RCT	2-4 weeks	10-31	PPG reduction: 20-30%	Large	Well tolerated
-------------------------------	-----	-----------	-------	-----------------------	-------	----------------

RCT = Randomized Controlled Trial; FBG = Fasting Blood Glucose; PPG = Postprandial Glucose; GI = Gastrointestinal

8. CHALLENGES AND LIMITATIONS

Several significant challenges limit the widespread clinical adoption of herbal medicines in diabetes management. Standardization remains a critical issue, as the content of bioactive compounds can vary dramatically between different preparations, harvest seasons, geographic locations, and processing methods. This variability makes it difficult to establish consistent dosing regimens and predict therapeutic outcomes.

The quality of clinical evidence, while improving, remains insufficient for many herbal medicines. Many studies suffer from methodological limitations including small sample sizes, short study durations, lack of proper randomization and blinding, and inconsistent outcome measures. The heterogeneity in study populations, intervention protocols, and outcome assessments makes meta-analyses challenging and limits the strength of conclusions.

Regulatory frameworks for herbal medicines vary significantly between countries, creating confusion about quality standards, safety requirements, and therapeutic claims. In many jurisdictions, herbal medicines are regulated as dietary supplements rather than pharmaceuticals, resulting in less stringent quality control and safety monitoring requirements.

Healthcare provider education represents another significant barrier. Many healthcare professionals lack adequate knowledge about herbal medicines, their mechanisms of action, potential benefits, and safety considerations. This knowledge gap can lead to dismissive attitudes toward herbal therapies or inadequate monitoring of patients using herbal medicines.

9. FUTURE DIRECTIONS AND RESEARCH NEEDS

The future development of herbal medicines for diabetes management requires addressing current limitations through systematic research approaches. Standardization efforts should focus on developing validated analytical methods for quality control, establishing reference standards for major bioactive compounds, and implementing good manufacturing practices for herbal preparations.

Clinical research priorities include conducting larger, longer-duration randomized controlled trials with standardized herbal preparations, investigating optimal dosing regimens and treatment durations, evaluating combination therapies with conventional antidiabetic drugs, and assessing long-term safety profiles and cardiovascular outcomes.

Mechanistic research should continue to elucidate the molecular mechanisms of action, identify novel bioactive compounds with antidiabetic activity, investigate synergistic effects of multiple compounds within herbal preparations, and develop biomarkers for monitoring therapeutic responses.

Technological advances in areas such as nanotechnology for improved drug delivery, genomics for personalized herbal medicine approaches, and artificial intelligence for drug discovery and development optimization offer promising avenues for advancing herbal diabetes therapeutics.

10. CONCLUSION

Herbal medicines represent a valuable complementary approach to diabetes management, offering multiple mechanisms of action and generally favorable safety profiles. While the current evidence base supports the therapeutic potential of several herbal medicines, significant challenges

remain in standardization, clinical evidence quality, and regulatory frameworks.

The polypharmacological nature of herbal medicines may offer advantages over single-target synthetic drugs, particularly in addressing the complex pathophysiology of diabetes. However, rigorous scientific validation through high-quality clinical trials remains essential for establishing herbal medicines as evidence-based therapeutic options.

Future research should focus on standardization, mechanism elucidation, and conducting robust clinical trials to establish optimal therapeutic protocols. With continued scientific investigation and appropriate regulatory oversight, herbal medicines may play an increasingly important role in comprehensive diabetes care, particularly in resource-limited settings where access to conventional pharmaceuticals may be restricted.

The integration of herbal medicines into diabetes management requires collaboration between traditional healers, researchers, healthcare providers, and regulatory agencies to ensure safe, effective, and evidence-based therapeutic approaches. As our understanding of herbal medicines continues to evolve, they may provide valuable tools for addressing the global diabetes epidemic while respecting traditional healing practices and cultural preferences.

REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation; 2021.
2. World Health Organization. Traditional medicine strategy: 2014-2023. Geneva: World Health Organization; 2013.
3. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care*. 2003;26(4):1277-94.
4. Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER. Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *J Ethnopharmacol*. 1990;30(3):295-300.
5. Shanmugasundaram ER, Rajeswari G, Baskaran K, Rajesh Kumar BR, Radha Shanmugasundaram K, Kizar Ahmath B. Use of *Gymnema sylvestre* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. *J Ethnopharmacol*. 1990;30(3):281-94.
6. Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ, Bignell AH. Improvement in glucose tolerance due to *Momordica charantia* (karela). *Br Med J (Clin Res Ed)*. 1981;282(6279):1823-4.
7. John AJ, Cherian R, Subhash HS, Cherian AM. Evaluation of the efficacy of bitter melon (*Momordica charantia*) as an oral hypoglycemic agent--a randomized controlled clinical trial. *Indian J Physiol Pharmacol*. 2003;47(3):363-5.
8. Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. *Eur J Clin Nutr*. 1990;44(4):301-6.
9. Gupta A, Gupta R, Lal B. Effect of *Trigonella foenum-graecum* (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. *J Assoc Physicians India*. 2001;49:1057-61.
10. Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. *Diabetes Care*. 2003;26(12):3215-8.
11. Davis PA, Yokoyama W. Cinnamon intake lowers fasting blood glucose: meta-analysis. *J Med Food*. 2011;14(9):884-9.
12. Leach MJ, Kumar S. Cinnamon for diabetes mellitus. *Cochrane Database Syst Rev*. 2012;9:CD007170.
13. Ashraf R, Khan RA, Ashraf I. Garlic (*Allium sativum*) supplementation with standard antidiabetic agent provides better diabetic control in type 2 diabetes

- patients. *Pak J Pharm Sci.* 2011;24(4):565-70.
14. Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertension: the AGE at Heart trial. *Integr Blood Press Control.* 2016;9:9-21.
 15. Vuksan V, Sievenpiper JL. Herbal remedies in the management of diabetes: lessons learned from the study of ginseng. *Nutr Metab Cardiovasc Dis.* 2005;15(3):149-60.
 16. Reay JL, Scholey AB, Kennedy DO. *Panax ginseng* (G115) improves aspects of working memory performance and subjective ratings of calmness in healthy young adults. *Hum Psychopharmacol.* 2010;25(6):462-71.
 17. Huseini HF, Kianbakht S, Hajiaghaee R, Dabaghian FH. Anti-hyperglycemic and anti-hypercholesterolemic effects of *Aloe vera* leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. *Planta Med.* 2012;78(4):311-6.
 18. Choi YK, Cho GS, Hwang S, Kim BW, Heo TH, Kim YJ, et al. Methylglyoxal reduction in *Panax ginseng* with steaming process. *Food Chem Toxicol.* 2012;50(11):4028-32.
 19. Judy WV, Hari SP, Stogsdill WW, Judy JS, Naguib YM, Passwater R. Antidiabetic activity of a standardized extract (*Glucosol*) from *Lagerstroemia speciosa* leaves in Type II diabetics. A dose-dependence study. *J Ethnopharmacol.* 2003;87(1):115-7.
 20. Stohs SJ, Miller H, Kaats GR. A review of the efficacy and safety of banaba (*Lagerstroemia speciosa* L.) and corosolic acid. *Phytother Res.* 2012;26(3):317-24.
 21. Khandouzi N, Shidfar F, Rajab A, Rahideh T, Hosseini P, Mir Taheri M. The effects of ginger on fasting blood sugar, hemoglobin a1c, apolipoprotein B, apolipoprotein a-I and malondialdehyde in type 2 diabetic patients. *Iran J Pharm Res.* 2015;14(1):131-40.
 22. Mahluji S, Attari VE, Mobasser M, Payahoo L, Ostadrahimi A, Golzari SE. Effects of ginger (*Zingiber officinale*) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients. *Int J Food Sci Nutr.* 2013;64(6):682-6.
 23. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. *Diabetes Care.* 2012;35(11):2121-7.
 24. Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. *Evid Based Complement Alternat Med.* 2013;2013:636053.
 25. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TP. Indian herbs and herbal drugs used for the treatment of diabetes. *J Clin Biochem Nutr.* 2007;40(3):163-73.
 26. Marles RJ, Farnsworth NR. Antidiabetic plants and their active constituents. *Phytomedicine.* 1995;2(2):137-89.
 27. Jung M, Park M, Lee HC, Kang YH, Kang ES, Kim SK. Antidiabetic agents from medicinal plants. *Curr Med Chem.* 2006;13(10):1203-18.
 28. Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. *J Ethnopharmacol.* 2004;92(1):1-21.
 29. Prabhakar PK, Doble M. Mechanism of action of natural products used in the treatment of diabetes mellitus. *Chin J Integr Med.* 2011;17(8):563-74.
 30. Bnouham M, Ziyyat A, Mekhfi H, Tahri A, Legssyer A. Medicinal plants with potential antidiabetic activity - a review of ten years of herbal medicine research (1990-2000). *Int J Diabetes Metab.* 2006;14:1-25.
 31. Ayyanar M, Sankarasivaraman K, Ignacimuthu S. Traditional herbal medicines used for the treatment of diabetes among two major tribal groups in South Tamil Nadu, India.

- Ethnobotanical Leaflets. 2008;12:276-80.
32. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. *J Ethnopharmacol.* 2002;81(1):81-100.
 33. Alarcon-Aguilara FJ, Roman-Ramos R, Perez-Gutierrez S, Aguilar-Contreras A, Contreras-Weber CC, Flores-Saenz JL. Study of the anti-hyperglycemic effect of plants used as antidiabetics. *J Ethnopharmacol.* 1998;61(2):101-10.
 34. Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. *Diabetes Care.* 1989;12(8):553-64.
 35. Cazarolli LH, Zanatta L, Alberton EH, Figueiredo MS, Folador P, Damazio RG, et al. Flavonoids: cellular and molecular mechanism of action in glucose homeostasis. *Mini Rev Med Chem.* 2008;8(10):1032-8.
 36. Gomes A, Vedasiromoni JR, Das M, Sharma RM, Ganguly DK. Anti-hyperglycemic effect of black tea (*Camellia sinensis*) in rat. *J Ethnopharmacol.* 1995;45(3):223-6.
 37. Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, Flanagan VP, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. *J Agric Food Chem.* 2004;52(1):65-70.
 38. Imparl-Radosevich J, Deas S, Polansky MM, Baedke DA, Ingebritsen TS, Anderson RA, et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. *Horm Res.* 1998;50(3):177-82.
 39. Persaud SJ, Al-Majed H, Raman A, Jones PM. *Gymnema sylvestre* stimulates insulin release in vitro by increased membrane permeability. *J Endocrinol.* 1999;163(2):207-12.
 40. Al-Romaiyan A, Liu B, Asare-Anane H, Maity CR, Chatterjee SK, Koley N, et al. A novel *Gymnema sylvestre* extract stimulates insulin secretion from human islets in vivo and in vitro. *Phytother Res.* 2010;24(9):1370-6.
 41. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. *J Nat Prod.* 1981;44(6):648-55.
 42. Welihinda J, Karunanayake EH, Sheriff MH, Jayasinghe KS. Effect of *Momordica charantia* on the glucose tolerance in maturity onset diabetes. *J Ethnopharmacol.* 1986;17(3):277-82.
 43. Ribes G, Sauvaire Y, Da Costa C, Baccou JC, Loubatieres-Mariani MM. Antidiabetic effects of subfractions from fenugreek seeds in diabetic dogs. *Proc Soc Exp Biol Med.* 1986;182(2):159-66.
 44. Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, et al. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. *Diabetes.* 1998;47(2):206-10.
 45. Hannan JM, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt PR, et al. Soluble dietary fibre fraction of *Trigonella foenum-graecum* (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. *Br J Nutr.* 2007;97(3):514-21.
 46. Thomson M, Al-Qattan KK, Al-Sawan SM, Alnaqeeb MA, Khan I, Ali M. The use of ginger (*Zingiber officinale* Rosc.) as a potential anti-inflammatory and antithrombotic agent. *Prostaglandins Leukot Essent Fatty Acids.* 2002;67(6):475-8.
 47. Mahesh T, Menon VP. Quercetin alleviates oxidative stress in streptozotocin-induced diabetic rats. *Phytother Res.* 2004;18(2):123-7.
 48. Brahmachari G. Bio-flavonoids with promising antidiabetic potentials: a critical survey. *Res Rep Biochem.* 2011;1:1-13.
 49. Pinent M, Blay M, Blade MC, Salvado MJ, Arola L, Ardevol A. Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and

- insulinomimetic activity in insulin-sensitive cell lines. *Endocrinology*. 2004;145(11):4985-90.
50. Vessal M, Hemmati M, Vasei M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. *Comp Biochem Physiol C Toxicol Pharmacol*. 2003;135C(3):357-64.
 51. Ghosh S, Suryawanshi SA. Effect of *Vinca rosea* extracts in treatment of alloxan diabetes in male albino rats. *Indian J Exp Biol*. 2001;39(8):748-59.
 52. Chakravarthy BK, Gupta S, Gambhir SS, Gode KD. Pancreatic beta-cell regeneration--a novel antidiabetic mechanism of *Pterocarpus marsupium* Roxb. *Indian J Pharmacol*. 1980;12(2):123-7.
 53. Andallu B, Radhika B, Suryakantham V. Effect of aswagandha, ginger and mulberry on hyperglycemia and hyperlipidemia. *Plant Foods Hum Nutr*. 2003;58(3):1-7.
 54. Kar A, Choudhary BK, Bandyopadhyay NG. Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. *J Ethnopharmacol*. 2003;84(1):105-8.
 55. Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. *Altern Med Rev*. 2003;8(1):20-7.
 56. Ernst E, White AR. The BBC survey of complementary medicine use in the UK. *Complement Ther Med*. 2000;8(1):32-6.
 57. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. *Prev Med*. 2002;35(2):166-73.
 58. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, et al. Heavy metal content of ayurvedic herbal medicine products. *JAMA*. 2004;292(23):2868-73.
 59. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. *Arch Intern Med*. 1998;158(20):2200-11.
 60. Fugh-Berman A. Herb-drug interactions. *Lancet*. 2000;355(9198):134-8.
 61. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. *Drug Metab Rev*. 2003;35(1):35-98.
 62. Rotblatt M, Ziment I. Evidence-based herbal medicine. Philadelphia: Hanley & Belfus; 2002.
 63. Barnes J, Anderson LA, Phillipson JD. Herbal medicines. 3rd ed. London: Pharmaceutical Press; 2007.
 64. WHO Expert Committee on Diabetes Mellitus. Second report. Geneva: World Health Organization; 1980. WHO Technical Report Series, No. 646.
 65. American Diabetes Association. Standards of medical care in diabetes--2021. *Diabetes Care*. 2021;44(Suppl 1):S1-S232.